NFL BIOSCIENCES (EPA:ALNFL)

REGULATED PRESS RELEASE

published on 05/31/2024 at 17:45, 6 months 21 days ago

NFL BIOSCIENCES: RESULTS OF THE COMBINED GENERAL MEETING OF MAY 30, 2024
REGULATED PRESS RELEASE

published on 05/29/2024 at 08:00, 6 months 23 days ago

NFL BIOSCIENCES : Presentation of the study results conducted with the CEA at the Albatross congress
REGULATED PRESS RELEASE

published on 05/21/2024 at 08:00, 7 months ago

NFL BIOSCIENCES: POSITIVE FDA RESPONSE FOLLOWING THE PRE-IND APPLICATION FOR NFL-301 FOR REDUCING ALCOHOL CONSUMPTION
REGULATED PRESS RELEASE

published on 04/18/2024 at 08:00, 8 months 3 days ago

NFL Biosciences further strengthens its operational team with the arrival of a Head of Development and Manufacturing
BRIEF

published on 04/12/2024 at 07:50, 8 months 9 days ago

NFL Biosciences Successfully Raises Over €3 Million in Capital Increase

NFL Biosciences Capital Increase Biopharmaceutical NFL-101 NFL-301
REGULATED PRESS RELEASE

published on 04/12/2024 at 07:45, 8 months 9 days ago

Successful capital increase for NFL Biosciences with over €3 million raised
NFL Biosciences successfully raises over €3 million in capital increase, securing funds for upcoming Phase 3 clinical trial of NFL-101 and advancing development of NFL-301. New shares to be listed on Euronext Growth Paris on April 16, 2024

NFL Biosciences Capital Increase NFL-101 Phase 3 Clinical Trial NFL-301
BRIEF

published on 04/11/2024 at 17:50, 8 months 10 days ago

NFL Biosciences Initiates €3 Million Fundraising Through Capital Increase

NFL Biosciences Addiction Treatment Fundraising Clinical Trials Capital Increase
REGULATED PRESS RELEASE

published on 04/11/2024 at 17:45, 8 months 10 days ago

NFL Biosciences launches a fundraising round for 3 million euros through a capital increase
NFL Biosciences launches a fundraising round for 3 million euros through a capital increase, aiming to support Phase 3 clinical trial for NFL-101 and development of NFL-301 drug candidates

NFL Biosciences Capital Increase NFL-101 Phase 3 Clinical Trial Fundraising Round
REGULATED PRESS RELEASE

published on 04/02/2024 at 08:00, 8 months 19 days ago

NFL BIOSCIENCES SHOWCASES THE RESULTS OF ITS STUDIES TO THE SCIENTIFIC AND PHARMACEUTICAL COMMUNITIES
REGULATED PRESS RELEASE

published on 03/29/2024 at 17:45, 8 months 23 days ago

NFL BIOSCIENCES: 2023 FULL-YEAR BUSINESS AND EARNINGS UPDATE

Published on 12/21/2024 at 01:30, 1 day 3 hours ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 1 day 3 hours ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 1 day 4 hours ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 1 day 4 hours ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 1 day 5 hours ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 1 day 4 hours ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 1 day 4 hours ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 1 day 9 hours ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 1 day 9 hours ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day 10 hours ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 16 hours 34 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 10 hours ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 10 hours ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 14 hours ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days 10 hours ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE

News